Skip to content
Screener

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Amgen logo
AmgenAMGN
26.7%-3.7pp
Incyte logo
IncyteINCY
34%+12.3pp
PVL
Palvella TherapeuticsPVLA
-99.8%-34.2pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-153,231%-156,630pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-226.6%-84.9pp

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Calculated from Arcutis Biotherapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026. Open the filing →

Filed
May 6, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001787306-26-000040

FAQ

What is Arcutis Biotherapeutics, Inc.'s free cash flow margin?
Arcutis Biotherapeutics, Inc. (ARQT) reported free cash flow margin of -52.5% in Q1 2025.
How has Arcutis Biotherapeutics, Inc.'s free cash flow margin changed year-over-year?
Arcutis Biotherapeutics, Inc.'s free cash flow margin increased by 71.9% year-over-year, from -186.7% to -52.5%.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s free cash flow margin?
Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s free cash flow margin has grown at a -91.0% compound annual growth rate (CAGR), from -7,000.8% to -57.1%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Arcutis Biotherapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude